FGF-Receptors and PD-L1 in Anaplastic and Poorly Differentiated Thyroid Cancer: Evaluation of the Preclinical Rationale

BACKGROUND: Treatment options for poorly differentiated (PDTC) and anaplastic (ATC) thyroid carcinoma are unsatisfactory and prognosis is generally poor. Lenvatinib (LEN), a multi-tyrosine kinase inhibitor targeting fibroblast growth factor receptors (FGFR) 1-4 is approved for advanced radioiodine r...

Descripción completa

Detalles Bibliográficos
Autores principales: Adam, Pia, Kircher, Stefan, Sbiera, Iuliu, Koehler, Viktoria Florentine, Berg, Elke, Knösel, Thomas, Sandner, Benjamin, Fenske, Wiebke Kristin, Bläker, Hendrik, Smaxwil, Constantin, Zielke, Andreas, Sipos, Bence, Allelein, Stephanie, Schott, Matthias, Dierks, Christine, Spitzweg, Christine, Fassnacht, Martin, Kroiss, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8406771/
https://www.ncbi.nlm.nih.gov/pubmed/34475850
http://dx.doi.org/10.3389/fendo.2021.712107

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8406771/
https://www.ncbi.nlm.nih.gov/pubmed/34475850
http://dx.doi.org/10.3389/fendo.2021.712107

Ejemplares similares